KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLand & ImprovementsLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Receivables (2016 - 2025)

Historic Receivables for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Q4 2025 value amounting to $3.7 billion.

  • Teva Pharmaceutical Industries' Receivables rose 2124.88% to $3.7 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $3.7 billion, marking a year-over-year increase of 2124.88%. This contributed to the annual value of $3.7 billion for FY2025, which is 2124.88% up from last year.
  • According to the latest figures from Q4 2025, Teva Pharmaceutical Industries' Receivables is $3.7 billion, which was up 2124.88% from $3.8 billion recorded in Q3 2025.
  • Over the past 5 years, Teva Pharmaceutical Industries' Receivables peaked at $4.6 billion during Q1 2021, and registered a low of $3.1 billion during Q4 2024.
  • For the 5-year period, Teva Pharmaceutical Industries' Receivables averaged around $3.8 billion, with its median value being $3.7 billion (2022).
  • As far as peak fluctuations go, Teva Pharmaceutical Industries' Receivables plummeted by 2084.54% in 2023, and later skyrocketed by 2124.88% in 2025.
  • Over the past 5 years, Teva Pharmaceutical Industries' Receivables (Quarter) stood at $4.5 billion in 2021, then fell by 18.39% to $3.7 billion in 2022, then decreased by 7.77% to $3.4 billion in 2023, then decreased by 10.27% to $3.1 billion in 2024, then rose by 21.25% to $3.7 billion in 2025.
  • Its Receivables stands at $3.7 billion for Q4 2025, versus $3.8 billion for Q3 2025 and $3.6 billion for Q2 2025.